home / stock / iphyf / iphyf quote
Last: | $2.13 |
---|---|
Change Percent: | 0.0% |
Open: | $2.13 |
Close: | $2.13 |
High: | $2.13 |
Low: | $2.13 |
Volume: | 2,000 |
Last Trade Date Time: | 05/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.13 | $2.13 | $2.13 | $2.13 | $2.13 | 2,000 | 05-03-2024 |
$2.65 | $2.43 | $2.65 | $2.65 | $2.43 | 300 | 04-02-2024 |
$2.58 | $2.39 | $2.58 | $2.65 | $2.39 | 800 | 03-29-2024 |
$2.58 | $2.39 | $2.58 | $2.65 | $2.39 | 800 | 03-28-2024 |
$2.3405 | $2.3405 | $2.3405 | $2.3405 | $2.3405 | 200 | 03-27-2024 |
$2.395 | $2.395 | $2.395 | $2.395 | $2.395 | 100 | 03-19-2024 |
$2.44 | $2.44 | $2.44 | $2.44 | $2.44 | 100 | 03-11-2024 |
$2.52 | $2.52 | $2.52 | $2.52 | $2.52 | 200 | 03-06-2024 |
$2.84 | $0 | $2.84 | $0 | $0 | 5 | 01-05-2024 |
$2.84 | $2.895 | $2.84 | $2.895 | $2.84 | 300 | 01-01-2024 |
$2.84 | $2.895 | $2.84 | $2.895 | $2.84 | 300 | 12-29-2023 |
$2.65 | $2.65 | $2.65 | $2.65 | $2.65 | 200 | 12-27-2023 |
$2.756 | $2.66 | $2.756 | $2.756 | $2.66 | 1,200 | 12-25-2023 |
$2.756 | $2.66 | $2.756 | $2.756 | $2.66 | 1,200 | 12-22-2023 |
$2.7 | $2.77 | $2.7 | $2.77 | $2.7 | 625 | 12-21-2023 |
$2.55 | $2.594 | $2.55 | $2.594 | $2.55 | 600 | 12-11-2023 |
$2.37 | $2.37 | $2.37 | $2.37 | $2.37 | 100 | 12-07-2023 |
$2.44 | $2.44 | $2.44 | $2.48 | $2.44 | 500 | 12-04-2023 |
$2.39 | $2.39 | $2.39 | $2.39 | $2.39 | 200 | 11-14-2023 |
$2.35 | $2.35 | $2.35 | $2.35 | $2.35 | 1,000 | 10-30-2023 |
News, Short Squeeze, Breakout and More Instantly...
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) will hold its Annual General Meeting of Shareholders (“ AGM ”) at 10:30 a.m. CEST on May 23, 2024 in its headquarters, 117 avenue de Lumi...
Partner Sanofi advances SAR443579 / IPH6101, ANKET ® platform lead asset, a trifunctional anti-CD123 NKp46xCD16 NK cell engager, to Phase 2 dose expansion in blood cancers Dosing of the first patient in the dose expansion part of the trial triggers a €4m milestone paym...
IPH45 is a novel and differentiated exatecan-Antibody Drug Conjugate targeting Nectin-4 In PDX models of urothelial tumors, IPH45 has stronger activity than approved Nectin-4 targeting EV. IPH45 shows anti-tumor efficacy in various solid tumor and EV-refractory models Prec...